Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

This study has been completed.
Sponsor:
Collaborator:
Medarex
Information provided by:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00289640
First received: February 9, 2006
Last updated: February 27, 2010
Last verified: January 2009